ClinicalTrials.gg
RecruitingNCT07063329Updated Oct 28, 2026

Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive

A Phase 1/2 interventional study of PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy and PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy in NSCLC (Non-small Cell Lung Cancer), sponsored by Avistone Pharmaceutical(Ningbo)Co., LTD.. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Avistone Pharmaceutical(Ningbo)Co., LTD. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.
Updated Oct 28, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
108
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing andamertinib in Carcinoma, Non-Small-Cell Lung — 9 open to participants now, 10 under way, 2 of them phase 3. andamertinib · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
7th of 11
108 · median 120
Started
2025
with 1 other
Phase 1/2
3 of 11
3 open now
Registered
8th of 11
by date
Lead sponsor
1 of 11
Avistone Pharmaceutical(Ningbo)Co., LTD.

Among the 11 studies testing andamertinib in Carcinoma, Non-Small-Cell Lung, this one is the 7th largest by planned enrollment, is one of 2 that started in 2025, is one of 3 in phase 1/2, and was the 8th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

9 of the 11 studies testing andamertinib in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About andamertinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing andamertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Tyrosine Kinase Inhibitor (TKI) that targets Epidermal Growth Factor Receptor (EGFR) mutations. Unfortunately, despite the benefit observed for patients treated with EGFR-TKI, the vast majority of cancers are expected to develop resistance to the drug over time. The exact reasons why resistance develops are not fully understood but based upon clinical research it is hoped that combining PLB1004 with another type of anti-cancer therapy known as chemotherapy will delay the onset of resistance and the worsening of a patient's cancer.

In recent years, clinical studies on the combination of EGFR-TKI and chemotherapy have made important progress, suggesting that the combination of EGFR-TKI and chemotherapy further enhances the therapeutic benefit in EGFR-mutant positive NSCLC.

Both preclinical and clinical data indicate that PLB1004 exhibit good antitumor activity and relatively durable efficacy in NSCLC patients with EGFR mutations. They can reduce tumor burden, control tumor progression, and improve the survival benefit of patients, which is expected to provide an effective treatment option for such patients.

Read the detailed description

This study is a multicenter, open-label, dose-escalation and dose-expansion Ib/II phase study, aiming to evaluate the clinical safety, tolerability, PK and preliminary efficacy of PLB1004 combined with platinum-based doublet chemotherapy in NSCLC patients with EGFR mutations. The study consists of two parts: the phase Ib dose-escalation study and dose-expansion study, as well as the phase II clinical study. The target population of the phase Ib study is patients with confirmed locally advanced or metastatic NSCLC harboring EGFR mutations who have received or not received systemic antitumor therapy. The II phase clinical study sets up two cohorts. Cohort 1: patients with confirmed locally advanced or metastatic NSCLC harboring EGFR mutations who have received or not received systemic antitumor therapy; Cohort 2: patients with newly diagnosed resectable stage II-III NSCLC harboring EGFR mutations who have not received systemic antitumor therapy. A total of 79-108 patients are planned to be enrolled in the study, which is divided into a screening period, a treatment period and a follow-up period. During the administration of the study drug, follow-up will be conducted every 6 weeks in the first year and every 12 weeks from the second year onwards.

03

Conditions studied

  • NSCLC (Non-small Cell Lung Cancer)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Phase Ib Dose-escalation Part : Patients with or cytologically confirmed unresectable locally advanced (stage IIIB and IIIC) or (stage IV) NSCLC (according to the eighth edition of the AJCC lung cancer staging criteria) who have disease progression or intolerance after previous systemic treatment. Specific treatment requirements are as follows:

    • Patients with EGFR sensitive mutations: They must have received EGFR-TKI treatment. If only first/second-generation EGFR-TKIs were used, T790M negativity must be confirmed.
    • Patients with other EGFR mutations such as EGFR exon 20 insertion: They must have received platinum-based chemotherapy.

Phase Ib Dose-expansion part and Cohort 1 of Phase II: Patients with histologically or cytologically confirmed unresectable locally advanced (stage IIIB and IIIC) or metastatic (stage IV) NSCLC (according to the eighth edition of AJCC staging) who have not received previous systemic treatment or have received systemic treatment.

Cohort 2 of Phase II: Patients with histologically confirmed resectable stage II-III NSCLC (according to the eighth edition of AJCC staging) who have not received previous systemic treatment; among them, N2 is defined as single-station mediastinal lymph node non-bulky metastasis (lymph node short diameter \<2 cm) confirmed by imaging and pathology, with expected complete resection.

  • 2. Previous tumor tissue or pleural effusion or blood sample confirmed positive for EGFR mutation.
  • 3. at baseline according to 1.1 criteria.
  • 4. (ECOG) performance status score of 0 to 1.
  • 5. Estimated is more than 12 weeks.
  • 6. It has been medically evaluated and determined that the organ functions are good (within 7 days before the first study drug administration), including:

    • hematological : (ANC) ≥ 1.5 × 109/L, ≥ 90 g/L, ≥ 100 × 109/L. Platelet transfusion is not allowed within 3 days before testing, red blood cell transfusion is not allowed within 14 days before testing, and hematopoietic growth factor therapy is not allowed within 7 days before testing (pegylated granulocyte colony-stimulating factor [G-CSF] or erythropoietin [EPO] is within 14 days before testing).
    • liver function: serum ≤ 1.5× (in patients with known Gilbert syndrome, TBIL ≤ 3×ULN and direct bilirubin [DBIL] ≤ 1.5×ULN), serum /AST ≤ 2.5×ULN (for patients with confirmed liver metastases, ≤ 5.0×ULN).
    • Renal function: ≥ 50 mL/min.
    • coagulation function, defined as (including during anticoagulant therapy): (PT)\<1.5 × ULN, activated partial thromboplastin time (APTT)\<1.5 × ULN. If the subject is receiving anticoagulant therapy, they must receive a stable dose of anticoagulant at least one month prior to the first study administration.
  • 7. For cohort 2 of phase II: According to the surgeon's assessment, the total lung function can tolerate the planned pulmonary resection surgery.
  • 8. Female patients must use effective measures during the study and for 90 days after the end of study treatment, and must not breastfeed.Female patients with must have a negative serum pregnancy test within 7 days prior to the first dose.

Exclusion criteria

Exclusion Criteria:

  • 1. Participated in other therapeutic clinical trials within 28 days prior to the first dose。
  • 2. Patients underwent major organ surgery within 4 weeks prior to the first dose.or is expected to undergo major surgery during the study.
  • 3. Have received lung field or whole-brain radiotherapy within 28 days before the first study drug administration, or has received palliative local radiotherapy within 14 days before the first dose。
  • 4. Patients received antitumour traditional Chinese medicine within 1 weeks prior to the first dose,and received local anti-tumor drug therapy (such as thoracic or abdominal perfusion, etc.) within 14 days or within 5 half-lives (whichever is shorter)。
  • 5. Patients with other than tumors treated in this study (except: malignancies that are cured and have not recurred within 3 years prior to study entry; completely resected basal cell and squamous cell skin cancer; completely resected carcinoma in situ of any type).
  • 6. Adverse effects of previous anti-tumor therapy have not recovered to 5.0 grade rating of ≤ grade 1 (except for toxicity judged by the investigator be of no safety risk, such as alopecia, skin pigmentation, etc.)
  • 7. Have received systemic administration of potent inhibitors/inducers of within 7 days prior to the first dose of treatment/randomization or are expected to receive systemic administration of these drugs during study treatment.
  • 8. Patients have symptomatic central nervous system (CNS) , meningeal metastases, or a primary CNS tumor that is associated with progressive neurological symptoms.
  • 9. Patients have a history of severe cardiovascular disease, including but not limited to:

    • Mean corrected using Fridericia's formula (QTcF) from three times> 480ms at rest.
    • (NYHA) ≥ class II heart failure or (LVEF) \< 50%.
  • 10. Hypertension remains uncontrolled(systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg ) after aggressive antihypertensive therapy.
  • 11. Patients with active uncontrolled systemic bacterial, viral, or fungal infection despite optimal treatment Active hepatitis (: HBsAg-positive and HBV-DNA ≥ 2000 IU/ mL; Hepatitis B: antibody-positive , antibody-positive; Active syphilis, the onset period of keratitis or ulcerative keratitis.
  • 12. Patients are unable to swallow the drug orally, or has a condition that seriously affects gastrointestinal absorption in the judgment of the investigator.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    phase Ib Dose Escalation

    Drug: PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy

  • Experimental
    phase Ib Dose Expansion

    Drug: PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy

  • Experimental
    phase II Cohort1

    Drug: RP2D of PLB1004 oral once daily Combined with Platinum-Based Chemotherapy

  • Experimental
    phase II Cohort2

    Drug: RP2D of PLB1004 oral once daily Combined with Platinum-Based Chemotherapy

Interventions

  • DrugPLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy

    Drug page: Andamertinib

    For non-squamous NSCLC patients:Pemetrexed (500 mg/m2) plus carboplatin (AUC5) or cisplatin(75 mg/m²)on Day 1 of 21day cycles (every 3 weeks) , followed by PLB1004 80mg/160mg/240mg oral once daily。 For squamous NSCLC subjects: Docetaxel(75 mg/m² )or paclitaxel(175 mg/mg) plus carboplatin (AUC5) or cisplatin(75 mg/m²)on Day 1 of 21day cycles (every 3 weeks) , followed by PLB1004 80mg/160mg/240mg oral once daily.

  • DrugPLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy

    Drug page: Andamertinib

    Multiple doses of PLB1004 for oral administration. Platinum-based chemotherapy is combined and administered on Day 1 of 21days(every 3 weeks).

  • DrugRP2D of PLB1004 oral once daily Combined with Platinum-Based Chemotherapy

    RP2D of PLB1004 as determined during Phase Ib . Platinum-based chemotherapy is combined and administered on Day 1 of 21days(every 3 weeks).

  • DrugRP2D of PLB1004 oral once daily Combined with Platinum-Based Chemotherapy

    RP2D of PLB1004 as determined during Phase Ib,patients will undergo surgical treatment after 3 cycles of combination therapy with platinum-based chemotherapy. Post-surgery, they will receive an additional cycle of platinum-based chemotherapy followed by 13 cycles of maintenance therapy with PLB1004.

06

What researchers measure

Primary outcomes

  1. Phase Ib: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])

    To evaluate the tolerability and safety of PLB1004 combined with platinum-based doublet chemotherapy in patients with epidermal growth factor receptor (EGFR) mutation positive NSCLC

    Time frame: 12 months

  2. Phase Ib: Incidence of dose-limiting toxicities (DLT) as defined in the protocol

    To determine the maximum tolerated dose (MTD) and/or dose-limiting toxicities (DLT) of combination therapy of PLB1004 combined with platinum-based doublet chemotherapy in patients with EGFR mutation positive NSCLC

    Time frame: 12 months

  3. Phase Ib: Recommended Phase II Dose (RP2D)

    To determine the recommended phase II dose (RP2D) of PLB1004 in combination with platinum-based doublet chemotherapy in subjects with EGFR mutation positive NSCLC

    Time frame: 12 months

  4. Phase Ib: Overall Response Rate (ORR)

    ORR is defined as the proportion of subjects with confirmed best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1

    Time frame: 24 months

  5. Phase II: To evaluate the efficacy of PLB1004 in combination with platinum-based doublet chemotherapy at the RP2D in subjects with EGFR mutation positive locally advanced or metastatic NSCLC

    Objective response rate (ORR) as evaluated by the investigator according to RECIST v1.1

    Time frame: 36 months

  6. Phase II: To evaluate the efficacy of PLB1004 in combination with platinum-based doublet chemotherapy at the RP2D RP2D in newly diagnosed resectable stage II-III NSCLC subjects with EGFR mutation positive

    Major pathological response (MPR) evaluated by the blinded independent pathology review committee (BIPR)

    Time frame: 12 months

Secondary outcomes

  1. Cmax

    Single-dose PK parameters: Peak concentration (Cmax)

    Time frame: 12 months

  2. DOR

    Duration of response (DoR)

    Time frame: 36 months

  3. PFS

    Progression-Free Survival

    Time frame: 36 months

  4. Tmax

    Time to peak concentration (Tmax)

    Time frame: 12 months

  5. (AUC0-t)

    Evaluation of the area under the concentration-time curve (AUC0-t)

    Time frame: 12 months

  6. T 1/2

    Assessment of the first dose elimination half-life (T 1/2)

    Time frame: 12 months

  7. CL/F

    Assessment of apparent clearance rate of the first dose (CL/F)

    Time frame: 12 months

  8. Vz/F

    Apparent volume of distribution

    Time frame: 12 months

  9. DCR

    Disease Control Rate

    Time frame: 36 months

  10. OS

    Overall Survival

    Time frame: 36 months

  11. EFS

    Event-Free Survival

    Time frame: 36 months

  12. pCR

    pathological Complete Response

    Time frame: 36 months

  13. DFS

    Disease-Free Survival

    Time frame: 36 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Mar 2028, 30 months after the start.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 30 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Jul 14, 2025
StartActual
Aug 22, 2025
Primary completionEst.
Mar 8, 2028
CompletionEst.
Jul 8, 2028
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 28, 2026
Sites
1 site added. Shanghai Chest hospital is now Recruiting
Show site
  • Henan Cancer Hospital · Zhengzhou, China
Oct 28, 2026
Start date
Aug 8, 2025→Aug 22, 2025 (actual)
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Not yet recruiting→Recruiting
    1 site added. Shanghai Chest hospital is now Recruiting
    Show site
    • Henan Cancer Hospital · Zhengzhou, China
    Start date Aug 8, 2025→Aug 22, 2025 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07063329
Lead sponsor
Avistone Pharmaceutical(Ningbo)Co., LTD.
Responsible party
Sponsor
First posted
Jul 14, 2025
Start date
Aug 22, 2025
Primary completion
Mar 8, 2028 (estimated)
Completion
Jul 8, 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

Shun Lu M.D, Ph.D.
Contact
shunlu@sjtu.edu.cn
86-21-22200000
Shun Lu M.D, Ph.D.
principal investigator · Shanghai Chest Hospital
Deng Hou Master
study director · Avistone Pharmaceutical(Ningbo)Co., LTD.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Andamertinib

Start the discussion